<DOC>
	<DOCNO>NCT00002945</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Interleukin-2 may stimulate person 's white blood cell kill leukemia cell . PURPOSE : Phase III trial study effectiveness high-dose combination chemotherapy , peripheral stem cell transplantation , interleukin-2 treating patient acute myeloid leukemia .</brief_summary>
	<brief_title>High Dose Chemotherapy , Peripheral Stem Cell Transplantation , Interleukin-2 Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine relapse free survival patient previously untreated de novo secondary acute myeloid leukemia treat high dose cytarabine idarubicin induction , high dose etoposide cyclophosphamide intensification , filgrastim ( G-CSF ) , melphalan , radiotherapy , autologous peripheral blood stem cell ( PBSC ) transplantation , interleukin-2 . - Correlate remission rate relapse free survival multidrug resistance phenotype patient treat regimen . - Determine stem cell content presence cell leukemia specific marker PBSC harvest follow high dose etoposide cyclophosphamide intensification . - Correlate NK cell expansion ( increase proportion absolute number ) interleukin-2 therapy follow autologous PBSC transplantation disease free survival . OUTLINE : Induction - Patients receive cytarabine IV 1 hour every 12 hour 6 day idarubicin IV 30 minute follow third , fifth , seventh dos cytarabine . Beginning 12 hour last dose cytarabine , patient receive filgrastim ( G-CSF ) subcutaneously ( SQ ) day blood count recover . Intensification - Patients receive etoposide IV 34.3 hour follow 1 hour later cyclophosphamide IV 2 hour 3 day . Beginning 24 hour last dose cyclophosphamide , patient receive G-CSF SQ day blood count recover . Peripheral blood stem cell ( PBSC ) harvest select CD34+ cell . Patients receive melphalan IV 1 hour day -4 follow total body irradiation day -3 , -2 , -1 . PBSC reinfused day 0 . When blood count recover , patient receive high dose interleukin-2 SQ day 1-10 follow low dose interleukin-2 SQ day 11-13 . Interleukin-2 treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Patients immunologic response 6 course interleukin-2 treatment may continue 6 additional course . PROJECTED ACCRUAL : Approximately 100 patient accrue study 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove de novo secondary acute myeloid leukemia classification M0M2 M4M7 No classification M3 No promyelocytic leukemia Prior medical condition allow : Myelodysplastic syndrome Aplastic anemia Paroxysmal nocturnal hemoglobinuria Myeloproliferative disorder except Philadelphia chromosome positive chronic myelogenous leukemia PATIENT CHARACTERISTICS : Age : Over 25 Performance status : Not specify Life expectancy : At least 4 week Hematopoietic : Not specify Hepatic : Bilirubin great 2 time normal SGOT great 2 time normal Alkaline phosphatase great 2 time normal Renal : Creatinine great 1.5 time normal Cardiovascular : Ejection fraction least 45 % No severe cardiovascular disease include myocardial infarction within past 6 month , uncontrolled symptomatic congestive heart failure , angina pectoris , multifocal cardiac arrhythmia Other : No uncontrolled diabetes mellitus No active malignancy No hypersensitivity E. coli derive drug preparation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy acute leukemia except hydroxyurea Prior chemotherapy allow malignancy medical condition Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow malignancy medical condition Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute monoblastic leukemia acute monocytic leukemia ( M5 )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>